サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1496885

抗リン脂質抗体症候群（APS）の世界市場：2024～2031年

Global Antiphospholipid Syndrome (APS) Market - 2024-2031

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
抗リン脂質抗体症候群（APS）の世界市場：2024～2031年
出版日: 2024年06月18日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

抗リン脂質抗体症候群（APS）の世界市場は、2023年に328億7,000万米ドルに達し、2031年には684億3,000万米ドルに達すると予測され、予測期間2024年～2031年のCAGRは9.6%で成長する見込みです。

抗リン脂質抗体症候群（APS）は、血管を閉塞する異常な血栓を形成する傾向増加を特徴とします。血栓は、脚、肺、腎臓や脾臓など臓器など、体内あらゆる血管で発生する可能性があります。抗リン脂質抗体症候群（APS）では、免疫系が抗リン脂質抗体と呼ばれる異常な抗体を産生し、こ抗体は脂肪分子に結合したタンパク質を標的とするため、血液が凝固しやすくなります。

市場は、治療薬臨床試験増加、抗リン脂質抗体症候群（APS）流行、研究開発高まりといった要因によって牽引されています。

市場力学

促進要因

抗リン脂質抗体症候群（APS）の臨床試験の増加

世界の抗リン脂質抗体症候群（APS）市場は、最近の様々な臨床試験により大きな成長を遂げています。抗リン脂質抗体症候群（APS）は通常、病歴や臨床所見、画像所見に基づいて診断されます。

抗リン脂質抗体症候群（APS）の治療における先進的な研究臨床開発は、市場の成長を加速させるのに役立っています。例えば、2022年12月、山東大学のQilu Hospitalは、全身性エリテマトーデス（SLE）に続発する抗リン脂質抗体症候群（APS）に対するTelitaciceptに続くリツキシマブ療法の有効性と安全性に関する臨床試験を実施しました。本試験では、Telitacicept 160mgを週1回、24週間投与します。

さらに、2022年3月、Hopitaux de Paris社は、「原発性産科性抗リン脂質抗体症候群（APS）における、合併症のない正期妊娠を得るための通常の内科的治療に対するヒドロキシクロロキンによる補助治療の有益性の評価」に関する介入試験を実施しました。

この臨床試験は、産科的抗リン脂質抗体症候群（APS）（APS）において、従来の治療にヒドロキシクロロキンを追加するかしないかの有益性を評価するものです。このように、上記の要因から、市場は予測期間中に盛り上がると予想されます。

さらに、抗リン脂質抗体症候群（APS）治療における革新的な研究開発を行う業界の主要企業は、この市場の成長を促進するでしょう。例えば、2023年11月、Hospital for Special Surgery（HSS）の研究者らによる新たな研究で、抗リン脂質抗体症候群（APS）（APS）の初期高リスク抗体プロファイルは、小児患者では高水準にとどまる傾向があることが判明しました。この結果は、米国リウマチ学会（ACR）の年次総会であるConvergence 2023のポスターセッションで発表されました。

また、2022年11月、ジュネーブ大学病院（HUG）、ジュネーブ大学（UNIGE）、およびそのスピンオフ企業であるEndotelix社は、抗リン脂質抗体症候群（APS）の原因となる抗体に対する最良の標的分子を創製しました。この発見により、新しいスクリーニング検査が開発されることになります。この自己免疫症候群は、脳卒中や心臓発作の原因となる血栓症を引き起こします。

制約

抗リン脂質抗体症候群（APS）に伴う合併症、高額な治療費、認識不足と誤診または過小診断、限られた治療オプション、診断と臨床試験の実施における課題などの要因が市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 抗リン脂質抗体症候群（APS）の臨床試験の増加
      • 抗リン脂質抗体症候群（APS）の有病率と発症率の増加
    • 抑制要因
      • 抗リン脂質抗体症候群（APS）に伴う合併症
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析
  • ロシア・ウクライナ戦争影響分析
  • DMIの見解

第6章 タイプ別

  • 原発性抗リン脂質抗体症候群（APS）
  • 二次性抗リン脂質抗体症候群（APS）
  • 劇症型抗リン脂質抗体症候群（APS）

第7章 治療法別

  • 薬物療法
    • ワルファリン
    • エノキサパリン
    • リツキシマブ
    • ヒドロキシクロロキン
  • 予防療法
  • その他

第8章 投与経路別

  • 経口
  • 非経口
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第12章 企業プロファイル

  • Genentech Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • F. Hoffmann-La Roche
  • Sanofi S.A
  • LGM Pharma
  • Taro Pharmaceuticals
  • Apotex PharmaChem
  • Teva Pharmaceuticals
  • Bristol Myers Squibb
  • Qilu Pharmaceuticals
  • Sigma Aldrich

第13章 付録

目次
Product Code: PH8495

Overview

The global antiphospholipid syndrome market reached US$ 32.87 billion in 2023 and is expected to reach US$ 68.43 billion by 2031 growing with a CAGR of 9.6% during the forecast period 2024-2031.

Antiphospholipid Syndrome is characterized by an increased tendency to form abnormal blood clots that block the blood vessels. The blood clot can develop in any blood vessel in the body such as in the legs, lungs, and other organs, such as the kidneys and spleen. In antiphospholipid syndrome, the immune system produces abnormal antibodies called antiphospholipid antibodies that target the proteins attached to fat molecules which makes the blood more likely to clot.

The market is driven by factors such as the increasing clinical trials of treatment drugs, the prevalence of antiphospholipid syndrome, and rising research and developments.

Market Dynamics

Drivers

Increasing Clinical Trials for Antiphospholipid Syndrome

The global antiphospholipid syndrome market has witnessed significant growth due to various recent clinical trials. Antiphospholipid syndrome is usually diagnosed based on medical history and clinical and imaging findings.

Advanced research clinical developments in treating antiphospholipid syndrome help to accelerate market growth. For instance, in December 2022, Qilu Hospital of Shandong University conducted a clinical trial on the Efficacy and Safety of Telitacicept Followed by rituximab Therapy on Antiphospholipid Syndrome Secondary to Systemic lupus erythematosus (SLE). The intervention involves Telitacicept 160mg given once a week for 24 weeks.

Moreover, in March 2022, Hopitaux de Paris conducted an interventional study on the Evaluation of the Benefit of Adjuvant Treatment with Hydroxychloroquine to the Usual Medical Management for Obtaining an Uncomplicated Term Pregnancy in Primary Obstetric Antiphospholipid Syndrome.

This clinical trial is to evaluate the benefit of the addition or no of hydroxychloroquine to conventional treatment in obstetric antiphospholipid syndrome (APS). Thus, due to the above factors, the market is expected to boost over the forecast period.

Moreover, key players in the industry developing innovative research studies in antiphospholipid syndrome treatments would drive this market growth. For instance, in November 2023, a new study by Hospital for Special Surgery (HSS) investigators found that an initial high-risk antibody profile for antiphospholipid syndrome (APS) tended to remain high in pediatric patients. The results were presented in a poster session at the American College of Rheumatology (ACR) Convergence 2023, the ACR's annual meeting.

Also, in November 2022, the Geneva University Hospitals (HUG), the University of Geneva (UNIGE), and their spin-off Endotelix created the best possible target molecule for the antibodies responsible for antiphospholipid syndrome. This discovery will enable a new screening test to be developed. This auto-immune syndrome leads to the thromboses responsible for strokes and heart attacks.

Restraints

Factors such as the complications associated with antiphospholipid syndrome, high treatment costs, lack of awareness & misdiagnoses or underdiagnoses, limited treatment options, and challenges in diagnosis & conducting clinical trials are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global antiphospholipid syndrome market is segmented based on type, treatment, route of administration, distribution channels, and region.

The medications segment accounted for approximately 54.3% of the global antiphospholipid syndrome market share

The medications segment is expected to hold the largest market share over the forecast period. The rising clinical trials of treatment drugs globally have contributed to the growing demand for antiphospholipid syndrome treatment.

According to clinicalTrials.gov, in January 2023, the University of Turin, Italy conducted a clinical trial on Belimumab Therapy for Refractory and Non-criteria Manifestations of antiphospholipid syndrome.

The primary objective of the BeLimumab Antiphospholipid Syndrome Trial (BLAST) is to evaluate the safety and tolerability of belimumab for up to 24 months in patients with persistent positivity and clinical features attributable that are resistance to warfarin and heparin.

Moreover, in January 2023, the Institute of Hematology & Blood Diseases Hospital conducted a clinical trial on the Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome with Secondary Thrombocytopenia.

This study aims to provide a new treatment option for the clinical treatment of antiphospholipid syndrome with secondary thrombocytopenia to drive this segment's growth.

Geographical Analysis

North America accounted for approximately 43.3% of the global antiphospholipid syndrome market share

North America region is expected to hold the largest market share over the forecast period The rising incidence and prevalence of APS, particularly among the aging population, are driving market growth in this region.

According to the Medspace publication in November 2023, the incidence of APS is approximately 5 cases per 100,000 persons per year, and the prevalence is approximately 40-50 cases per 100,000 persons.

In addition, major key players' presence and new drug launches & approvals would drive this market growth. For instance, in June 2022, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism directly after they have been treated with a blood thinner given by injection for at least five days.

Also, in October 2023, Bio-Rad Laboratories introduced the BioPlex 2200 Antiphospholipid Syndrome (APL-S) IgM kit is a multiplex flow immunoassay intended for the semi-quantitative detection of IgM antibodies to Cardiolipin (CE) and lBeta-2 Glycoprotein I (j32GPI) in human serum and plasma.

The BioPlex 2200 System is a fully automated, random access multiplex system that allows clinical laboratories to maximize efficiency for autoimmune, infectious disease, and specialty testing.

Market Segmentation

By Type

  • Primary Antiphospholipid Syndrome
  • Secondary Antiphospholipid Syndrome
  • Catastrophic Antiphospholipid Syndrome

By Treatment

  • Medications
    • Warfarin
    • Enoxaparin
    • Rituximab
    • Hydroxychloroquine
  • Prophylactic Therapy
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Distribution Channels

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the antiphospholipid syndrome market include Genentech Inc., F. Hoffmann-La Roche, Sanofi S.A, LGM Pharma, Taro Pharmaceuticals, Apotex PharmaChem, Teva Pharmaceuticals, Bristol Myers Squibb, Qilu Pharmaceuticals, Sigma Aldrich among others.

Key Developments

  • In February 2024, Werfen announced it had received the CE mark for its Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) reagents under the European Union's (EU) In Vitro Diagnostic Medical Devices Regulation (IVDR).

Why Purchase the Report?

  • To visualize the global antiphospholipid syndrome market segmentation based on type, treatment, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global antiphospholipid syndrome market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global antiphospholipid syndrome market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channels
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Clinical Trials of Antiphospholipid Syndrome
      • 4.1.1.2. Increasing Prevalence and Incidence of Antiphospholipid Syndrome
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with Antiphospholipid Syndrome
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Primary Antiphospholipid Syndrome
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Secondary Antiphospholipid Syndrome
  • 6.4. Catastrophic Antiphospholipid Syndrome

7. By Treatment

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 7.1.2. Market Attractiveness Index, By Treatment
  • 7.2. Medications
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 7.2.2.1. Warfarin
      • 7.2.2.2. Enoxaparin
      • 7.2.2.3. Rituximab
      • 7.2.2.4. Hydroxychloroquine
  • 7.3. Prophylactic Therapy
  • 7.4. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral
  • 8.4. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacy
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
  • 10.3. Introduction
    • 10.3.1. Key Region-Specific Dynamics
    • 10.3.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. U.S.
      • 10.3.6.2. Canada
      • 10.3.6.3. Mexico
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Germany
      • 10.4.7.2. U.K.
      • 10.4.7.3. France
      • 10.4.7.4. Italy
      • 10.4.7.5. Spain
      • 10.4.7.6. Rest of Europe
  • 10.5. South America
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. Brazil
      • 10.5.7.2. Argentina
      • 10.5.7.3. Rest of South America
  • 10.6. Asia Pacific
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.7.1. China
      • 10.6.7.2. India
      • 10.6.7.3. Japan
      • 10.6.7.4. South Korea
      • 10.6.7.5. Rest of Asia Pacific
  • 10.7. Middle East and Africa
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Product Benchmarking
  • 11.3. Company Share Analysis
  • 11.4. Key Developments and Strategies

12. Company Profiles

  • 12.1. Genentech Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. F. Hoffmann-La Roche
  • 12.3. Sanofi S.A
  • 12.4. LGM Pharma
  • 12.5. Taro Pharmaceuticals
  • 12.6. Apotex PharmaChem
  • 12.7. Teva Pharmaceuticals
  • 12.8. Bristol Myers Squibb
  • 12.9. Qilu Pharmaceuticals
  • 12.10. Sigma Aldrich

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us